Synergistic effects by combining CD73 blockade with other currently available anticancer agents, including anthracycline (254), radiation (160), anti-cytotoxic T-lymphocyte antigen (CTLA)-4 antibodies (255, 256), and anti-PD-1 antibodies (255) have also been reported and highlight the potential clinical application of CD73 target therapies in combination with other anticancer modalities to improve antitumor immune response as well as tumor death. Here, NT5E is linked to neoplasm.